This site is intended for health professionals only

EMA backs Glivec® for 3-year gastro treatment

teaser

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion to update the Glivec® (imatinib) label to include 36 months of treatment after surgery for adult patients with KIT (CD117)-positive gastrointestinal stromal tumours (GIST).

This extended treatment regimen has been shown to improve recurrence-free survival and overall survival for KIT+ GIST patients.

The CHMP opinion was based on data from a multicentre, open-label, Phase III clinical trial.

Article continues below this sponsored advert
Cogora InRead Image
Explore the latest advances in clinical care at events delivered by renowned experts from CofE
Advertisement

Results of the study, which were first presented in June 2011 at the American Society of Clinical Oncology plenary session, showed that at five years, 66% of patients taking Glivec for three years after surgery for KIT+ GIST remained free of cancer recurrence (primary endpoint), compared to 48% who had received Glivec for only one year after surgery (p<0.0001).

In addition, at five years, 92% of patients taking Glivec for three years after surgery were alive (secondary endpoint) compared to 82% who had received Glivec for only one year after surgery (p=0.019).

“This CHMP positive opinion marks another major milestone in the evolution of GIST treatment, which began almost a decade ago with the introduction of Glivec in the metastatic setting,” said Hervé Hoppenot, President, Novartis Oncology.

European Medicines Agency






Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine

×